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Abstract
Background: Tumor initiating cells (TICs) provide a new paradigm for developing original therapeutic strategies.
Methods: We screened for TICs in 47 human adult brain malignant tumors. Cells forming floating spheres in
culture, and endowed with all of the features expected from tumor cells with stem-like properties were obtained
from glioblastomas, medulloblastoma but not oligodendrogliomas.
Results: A long-term self-renewal capacity was particularly observed for cells of malignant glio-neuronal tumors
(MGNTs). Cell sorting, karyotyping and proteomic analysis demonstrated cell stability throughout prolonged
passages. Xenografts of fewer than 500 cells in Nude mouse brains induced a progressively growing tumor. CD133,
CD15/LeX/Ssea-1, CD34 expressions, or exclusion of Hoechst dye occurred in subsets of cells forming spheres, but
was not predictive of their capacity to form secondary spheres or tumors, or to resist high doses of temozolomide.
Conclusions: Our results further highlight the specificity of a subset of high-grade gliomas, MGNT. TICs derived
from these tumors represent a new tool to screen for innovative therapies.
Background
Tumor initiating cells (TICs) from various types of can-
cers have been isolated and characterized. The tumors
of origin range from glioblastomas and medulloblasto-
mas [1-6] to epithelial tumors of the breast [7], lung [8],
colon [9], and prostate [10]. Gliomas represent the
majority of primary tumors from the central nervous
system (CNS) [11]. Difficulties in clinical management
(e.g. treatment and prognosis) are related to the com-
plex identity of gliomas, which lack reliable morphologi-
cal and molecular signatures, precluding thus the
establishment of a clear cut classification discriminating
between different tumor subtypes [12].
Historically, it has been proposed that gliomas (astro-
cytomas and oligodendrogliomas) originate respectively
from mature astrocytes or oligodendrocytes. The fact
that these brain tumors frequently include a mixture of
cells expressing neuronal and glial markers, has recently
led to the alternative proposal that gliomas arise from
neural stem/progenitor cells. Support for this hypothesis
comes from mouse models in which changes in the
expression of oncogenes or tumor suppressors lead to
experimental tumors [13]. Neural progenitor cells are,
for example, more sensitive than differentiated astro-
cytes to the oncogenic effects of combined over-activa-
tion of Ras and Akt signaling pathways [14]. It should
however be kept in mind that glioblastomas, the most
malignant form of gliomas, can be generated in mice by
retroviral transduction of oncogenes into mature glial
cells [14-16]. In good agreement, the conversion of* Correspondence: herve.chneiweiss@inserm.fr1Glial Plasticity lab; Inserm UMR 894; University Paris Descartes; Paris, France
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mature astrocytes toward neural progenitors induced by
TGFa [17], a growth factor overexpressed early in the
development of human gliomas [18]sensitizes them to
cancerous transformation [19]. The isolation from
human glioblastoma biopsies of malignant cells that
express markers of neural stem cells supports the exis-
tence of tumor stem cells within gliomas [1-3,6]. Most
importantly, some of these cells exhibit the true proper-
ties of tumor initiating cells (TICs), including the ability
to give rise to a tumor identical to the one observed in
the patient upon orthotopic grafting in mouse brains
[1,3,6]. It remains, however, unknown whether these
TICs might help to discriminate between glioma sub-
types. Moreover, the design of specific therapies awaits
the identification of the molecular pathways presiding
over the maintenance of the properties of these tumor
stem cells.
Here, we sought for tumor stem-like cells in 47
human adult malignant glial tumors. We identified a
subset of glial tumors that contain at high frequency of
cells generating long-term self-renewing floating spheres
in vitro, and novel tumors in immunodeficient mice.
This subset corresponds to malignant glio-neuronal
tumors (MGNTs) [20]. MGNTs are World Health Orga-
nization grade III and IV tumors that always present
numerous glial fibrillary acidic protein (GFAP)- and a
few neurofilament protein (NFP)-positive tumor cells.
The other neuronal markers tested (NeuN, synaptophy-
sin, and chromogranin) are inconstantly expressed. Dis-
tinction of MGNTs from other malignant gliomas is of
clinical importance since gross total surgical resection of
these tumors is the major prognostic factor predicting
long-term survival [20]. Flow cytometry and 2D-SDS-
PAGE analyses showed stable and common proteomic
profiles of MGNT-derived tumor initiating cells growing
as floating spheres. These cells are highly resistant to
temozolomide and thus represent a novel tool to screen
for more efficient therapies.
Methods
Sample Classification
All of the samples were classified according to World
Health Organization guidelines (grade II, III or IV for
gliomas), and the classification of Sainte Anne Hospital
(low grade oligodendroglioma or type A, high grade oli-
godendroglioma or type B, glioblastomas and malignant
glio-neuronal tumors, [20]. The biopsies were collected
by a pathologist in the surgical room from July 2002 to
July 2005. All patients were 18 years old or older, had
signed a written agreement for participation to the
research project after having being informed of the
goals, potential interest of the research and methods.
This biomedical research was conducted according to
the declaration of Helsinki, to the French laws, and was
approved by the institutional review board of Ste Anne
Hospital, Paris. Anatomopathological diagnosis classified
tumors as glioblastoma multiformis (n = 6), Malignant
Glio-Neuronal Tumors (MGNTs, n = 15), medulloblas-
toma (n = 2), ganglioglioma (n = 1), oligodendroglioma
(n = 23). Immunolabeling of formalin-fixed, paraffin-
embedded tissue sections was performed as previously
described [20].
Cell cultures
Viable fragments were transferred to a beaker contain-
ing 0.25% trypsin in 0.1 mM EDTA (4:1), and slowly
stirred at 37°C for 30-60 min. Dissociated cells were pla-
ted in 75 cm2 tissue culture flasks plated at 2500-5000
cells/cm2 in Dulbecco’s modified Eagle’s: F-12 medium
(1:1) containing the N2, G5 (containing FGF and EGF)
and B27 supplements (all from Invitrogen, France).
After 2 to 47 days in culture, spheres bloomed from
clusters of adherent cells. They were dissociated in sin-
gle-cell suspension each week with a renewal of two
third of their culture medium.
Characterization of sphere-forming cells
Dissociated sphere-derived cells were plated in 18-mm
diameter wells in 1 ml volumes at a density of 200 000
cells/well. Cell proliferation/viability was evaluated using
the WST1 kit from Roche according to the manufac-
turer’s protocol. We verified that the results were the
same as those obtained by counting the absolute num-
ber of viable cells using trypan blue exclusion. Clonality
was evaluated in 96-well plates seeded at a cell density
of 1-200 cells/well/0.1 ml. The number of wells contain-
ing at least one secondary sphere was evaluated after
3-4 weeks of culture.
Flow cytometry analysis of cell surface antigens
Single-cell suspensions were incubated with fluoro-
chrome-conjugated monoclonal antibodies: fluorescein
(FITC)-coupled CD15, FITC-CD11b, FITC-CD45, phy-
coerythrin (PE)-coupled CD34, PE-Thy-1 (CD90), PE-
CD133 and phycoerythrin cyanin 5 (PC5)-coupled
CD34, PC5-CD56, and allophycocyanin (APC)-coupled
CD133. CD133 antibodies were from Miltenyi (France),
all others from Beckman-Coulter. Dead cells were
excluded from the analysis by 7-AAD. Acquisition was
performed on a Facscalibur (Becton Dickinson) and
viable cells were analyzed with Cellquest software.
Assessment of the neural differentiation potential
Cells were plated at a density of 5.000 cells/cm2 onto
polyornithine-coated glass coverslips and onto Lab-
Tek™ II Chamber Slide™ System (Nalge Nunc Interna-
tional) http://www.nuncbrand.com/page.aspx?ID=234 in
the presence of FCS or B27 (Invitrogen) for 2 to 14
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days. Multiple immunofluorescence assays for neural
antigens were performed as previously described [17,20].
Real-time RT-PCR
The theoretical and practical aspects of real-time quanti-
tative RT-PCR using the ABI Prism 7900 Sequence
Detection System (Perkin-Elmer Applied Biosystems)
have been described in detail elsewhere [21]. Briefly,
total RNA is reverse-transcribed before real-time PCR
amplification. Quantitative values are obtained from the
threshold cycle (Ct) number at which the increase in
the signal associated with exponential growth of PCR
products begins to be detected using PE Biosystems ana-
lysis software, according to the manufacturer’s manuals.
We also quantified transcripts of TBP gene, which
encodes the TATA box-binding protein as the endogen-
ous RNA control, and each sample was normalized on
the basis of its TBP content.
Results, expressed as N-fold differences in target gene
expression relative to the TBP gene, termed Ntarget,
were determined by the formula: Ntarget = 2ΔCtsample,
where ΔCt value of the sample was determined by sub-
tracting the Ct value of the target gene from the Ct
value of the TBP gene.
The Ntarget values of the samples were subsequently
normalized to a “basal mRNA level”, i.e. normalized to
the smallest amount of target gene mRNA detectable
and quantifiable by real-time quantitative RT-PCR
assays (target gene Ct value = 35; Ntarget value = 1).
The nucleotide sequences of primers for TBP and the
4 target genes are available on request. The thermal
cycling conditions comprised an initial denaturation
step at 95°C for 10 min and 50 cycles at 95°C for 15 s
and 65°C for 1 min. Experiments were performed with
duplicates for each data point.
Chromosome Analysis of neurosphere-derived cells
Cells were treated with medium containing 10 μg/ml
Colchicine for 1 to 2 hours, and resuspended in hypo-
tonic 1% sodium citrate at room temperature for 30
minutes. The cells were then washed in a methanol-
acetic acid (3:1, v/v) fixative solution for 30 minutes,
and spread onto clean dry slides. Q-banding staining
was then performed, and 10 metaphases were analyzed
for each sample.
Proteomic analysis
Cells were washed three times with PBS for 10 min with
gentle shaking, prior to lyses in buffer containing 8 M
urea, 4% CHAPS and 40 mM Tris. The protein pellets
were dissolved in isoelectric focusing buffer and quanti-
fied using the Micro BCA protein assay kit (Pierce).
First-dimension isoelectric focusing was performed with
the Ettan IPGphor system (Amersham Biosciences) at
20°C with a maximum current setting of 50 mA/strip.
Immobiline DryStrip gels (IPG stripes, Amersham Bios-
ciences) with a pH gradient of 3-10 or 4-7 and a length
of 13 cm were rehydrated in 250 μl sample solution,
containing 80 μg proteins. Prior to SDS-PAGE analysis,
IPG stripes were equilibrated in second-dimension equi-
libration buffer (6 M urea, 2% SDS, 50 mM Tris-HCl,
pH 8.8, 30% glycerol) containing 1% DTT (Sigma) to
reduce the disulfide bonds of the proteins. The second
dimension was carried out using 12.5% gradient
polyacrylamide gels at constant 20 mA current per gel.
Comparison of the protein maps was achieved using the
PD-Quest software according to the manufacturer
instructions (BioRad).
Results
Selection and expansion of cell-forming spheres from
adult human brain tumors
In order to preserve tissue architecture and improve sam-
ple handling as well as the versatility of the tests that may
be applied, we developed a two-step strategy for the 49
surgical samples of our survey. Tumor samples were first
sliced in the surgical room in fragments smaller than 1
mm3, and placed on surgical sponges bathed with culture
medium. Tumor fragments were either dissociated within
2 hours after surgery (28 out of 49, 58%), or incubated in
organotypic conditions for a maximal time of 2 weeks
prior dissociation. Tumor fragments cultured on surgical
sponges are viable and conserve the tumor architecture
for up to 6 weeks (additional file 1). In both cases, the
dissociated cells were plated at low density (<5 × 103
cells/cm2) in a serum-free medium containing EGF and
FGF2 (G5 supplement).
In twelve of the fifteen cultures of MGNTs, floating
cellular spheres were observed after 14 to 60 days in
culture, and could be amplified from 6 months up to 52
months. In contrast, none of the other 23 tumors classi-
fied as World Health Organization grade II or III oligo-
dendrogliomas (n = 9 and 14, respectively) generated
spheres up to 90 days, the time at which no viable cells
remained in the cultures. Similarly, two benign lesions,
one Taylor Dysplasia and one adult pilocytic astrocy-
toma, did not yield any sphere. A third in vitro behavior
pattern was observed for cells derived from three of the
six glioblastoma multiformis studied, two adult medullo-
blastomas and one adult ganglioglioma. In these cases,
spheres developed but stopped dividing after 2 to 5
months of culture, and disappeared suggesting limited
auto-renewal capabilities (Table 1).
These data extended previous reports of absence of
EGF/FGF2-responsive clonogenic precursors in
oligodendrogliomas [2-4,22]. They revealed the unique
ability of MGNTs to yield cellular spheres that could be
amplified for very long periods.
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MGNT contain cells endowed with long-term self-renewal
and clonal properties
MGNT cells were moderately proliferative but highly
clonogenic. The average proliferation rate, determined
using cultures derived from MGNT 1, 6 and 7 (TG1,
TG6 and TG7), was equal to 236% ± 27% within 48
hours. In two separate experiments, the percentage of
cells initiating-spheres, determined by plating 500 disso-
ciated cells in 6-well plates and assessing the number of
secondary spheres, reached 25-30%. Similar results were
obtained when cells were plated at a density of 200 cells
per well in 96-well plates (TG1, 28.9% ± 8.0; TG6,
15.5% ± 7.0; TG7, 15.6% ± 5.0, mean ± sem, n = 3)
(Table 2). Finally, 7 to 10% of the cells seeded at one
cell/well generated at least one secondary sphere after
one month in culture (TGI, 9 ± 3%, n = 4, TG6, 7 ±
1%, n = 3, TG7, 7 ± 2%, mean ± sem, n = 3). These
properties were reproducibly observed for TG1-cells
from week 40 to week 100, the latest time tested.
MGNT-derived cells forming spheres exhibit a neural
progenitor phenotype in vitro
Analysis was conducted with a panel of antibodies direc-
ted against antigens characteristic of stem/progenitor
cells of the CNS and other tissues, and of cells of the
neuronal and glial lineages (Figure 1A-D). Numerous
cells expressed nestin and the bHLH-transcription factor
Olig2 (Figure 1A, 1C and 1I), normally expressed in
stem/progenitor cells. A majority of cells were
immunoreactive for GFAP, an astroglial marker (Figure
1B and 1I), whereas a small population was immunor-
eactive for the neuronal marker ß3-tubulin (Figure 1D
and 1I). Each individual sphere exhibited cellular
heterogeneity.
When bFGF and EGF were removed and replaced by
serum, most but not all spheres underwent changes
characteristic of differentiation: they adhered rapidly to
the plastic substrate, the cells flattened and acquired a
fusiform shape. Cellular heterogeneity both between
spheres and within each sphere was maintained in these
conditions, as shown by immunocytochemical analysis
(Figure 1E-G and 1I). When treated with 0.5% FCS for
14 days, all cells exhibited nuclear Olig2-immunolabel-
ing (Figure 1G and 1I). In the presence of B27, a cock-
tail designed to promote neuron survival and
development in cultures of normal nervous tissue, 30%
of the cells within the spheres acquired the appearance
of neuron-like cells with a rich neurite-like branching,
and ß3-tubulin expression (Figure 1H and 1I). Interest-
ingly, a fraction of the differentiated cells co-expressed
neuronal and glial markers as in the original tumor (Fig-
ure 1F and 1I).
Cell surface phenotype and the functional state of
sphere-derived cells
The cell-surface phenotype of sphere-derived cells from
different MGNT cultures (TG1, TG6, TG7) was repeat-
edly characterized using flow cytometry and remained
stable over 6 months and up to 52 months for TG1, the
latest time tested (Figure 2). CD56/NCAM, CXCR4,
CD90/Thy-1, and VLA2, which are known to be express
by neural progenitors, were detected in over 90% of the
cells. A second group of proteins was detected in less
than 10% of the cells. They included CD15/Lex/ssea1,
described on neural stem cells [23], and CD34 synthe-
sized by stem/progenitor cells from several tissues, but
which so far has not been reported on neural cells.
CD34 is known to be also expressed by endothelial cells,
that may originate from neural stem cells in normal
Table 1 Summary of the brain tumor cultures. See text for details.
Tumor type Number of cases Number of cultures containing
floating cellular spheres
Self-renewal length ≤
6 months
Self-renewal length >
6 months
MGNT 15 12 0 12
Oligodendroglioma II 9 0 - -
Oligodendroglioma III 14 0 - -
Glioblastoma 6 3 3 0
Pilocytic astrocytoma 1 0 - -
Taylor Dysplasia 1 0 - -
Ganglioglioma 1 1 1 0
Medulloblastoma 2 2 2 0
Table 2 Clonal properties of MGNT derived glioma stem
cells
Culture name 200 cells/well 1 cell/well
TG1 28.9 ± 8 9 ± 3
TG6 15.5 ± 7.0 7 ± 1
TG7 15.6 ± 5.0 7 ± 2
Example of clonal properties of cell-initiating spheres derived from MGNT. The
cellular spheres were dissociated, and plated at 200 or 1 cell/well in 96-well
plates. The percentage of wells containing spheres is presented as mean ±
sem, n = 3.
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brains [24]. However, no expression was detected for the
endothelial-specific markers CD31 and VE-cadherin by
MGNT-derived cultured cells. Similarly, none of the
hematopoietic markers CD45, CD3, CD11b, CD14,
CD19, CD33, CD36, CD38 was expressed, thus exclud-
ing that CD34 expression reflected contamination by
endothelial or hematopoietic progenitors. Likewise, we
did not detect expression of the cytokine receptors c-kit
or Flt3, or CD44 and CD93. In addition, we looked for
CD133-immunoreactive cells that have been reported to
represent up to 50% of dissociated tumor cells examined
by flow cytometry [1-6]. In agreement with these data,
we found that 20 to 30% of cells isolated immediately
after tumor resection were positive for this antigen (n =
4). Surprisingly, only a few cultured cells expressed
CD133, suggesting a rapid down-regulation in vitro.
Furthermore, CD133+ as well as CD133- cells were able
to form floating spheres as well as to initiate tumors
upon brain grafting (see below). One may hypothesize
that CD133 expression is not a characteristic of a sub-
population of cells endowed with stem-like properties at
least in MGNTs, but rather depends on their
environment.
To determine if the sphere-forming capability segre-
gated according to CD34 or CD15 expression, we sorted
the negative and positive fractions from TG1, and TG6
cultures (week 35 to 90), and determined their ability to
generate spheres in culture. The ability to form spheres
segregated neither with CD15 nor with CD34 expression
(Table 3). A side population was identified using the
Hoechst 3342 dye. Cells excluding the dye amounted to
2-10% of the cellular population (2 independent experi-
ments). The capacity of the cells to form spheres (in
both primary and secondary assays) was independent of
their ability to exclude the dye, suggesting that this
property depends from the cell activation state rather
than its identity.
RT-PCR analysis was additionally used to seek for
transcripts usually observed in stem cells and considered
as involved in their self-renewal capacities. Oct 4,
Nanog, and hTERT transcripts were observed in all
MGNT-derived cells forming spheres analyzed (n = 3)
(Table 4). Of note, CD133 transcripts were always close
to the limit of detection (Table 4).
Molecular characterization of cells-forming spheres
was further performed using 2D-SDS-PAGE. The stabi-
lity of the proteomic profile of a given culture was
determined using TG1 cells at two different passages
(week 40 and week 160). The proteomic profiles of cells
isolated from the spheres were also compared between
Figure 1 Immunocytochemical characterization of cells derived from MGNT. MGNT-derived cells form spheres in culture and express neural
markers. Example of spheres from one tumor, TG1, cultured with FGF/EGF (A-D) or in the presence of 10% (E-F), or 0,5% FCS (G). A-D. In serum-
free medium, cells within spheres expressed nestin (green, A), GFAP (red, B), Olig2 (red, C) and low levels of ß3-tubulin (green, D). E-G. After 14
days in serum-containing medium, the numbers of cells expressing Nestin decreased (green, E), The differentiated cells retained nuclear Olig2
expression (red, G). Some cells exhibited co-immunolabelling for GFAP (red) and ß3-tubulin (green, F). H. ß3-tubulin-immunoreactive cells in
serum-free medium supplemented with B27. Nuclei were counterstained with DAPI or Topro. Scale bar = 40 μm. I. Quantification of cells
expressing nestin, GFAP, Olig2 and ß3-tubulin in serum-free medium containing EGF and bFGF, in medium supplemented with 0.5 and 10% FCS,
and in medium supplemented with B27.
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different MGNTs. Analysis after silver staining revealed
a very similar protein pattern for TG1 at both passages
examined, as well as between cells derived from distinct
patients (TG6, TG7) (Figure 3). Comparison of the pro-
tein maps using computer-assisted analysis (PD-Quest
software) showed a high coefficient of correlation (0,84
± 0.06). A differential subtractive approach comparing
protein patterns from cells collected from MGNT-
derived spheres and a frozen micro-dissected fragment
of the original tumor, allowed the MALDI-TOF identifi-
cation of a group of proteins enriched in cultured cells
(Table 5). The eight potential biomarkers identified
included the mannose-6-phosphate receptor binding
protein 1 reported on early stem cells [25], and two pro-
teins associated with multidrug resistance, Sorcin being
the most strikingly over-expressed. Sorcin mRNA and
protein levels have been reported in astrocytoma and
are positively correlated with the malignancy of the
tumor [26]. These data are consistent with the possibi-
lity that Sorcin expression signs for an enhanced occur-
rence of TICs in high-grade gliomas.
Altogether, these results demonstrate that cells form-
ing cells derived from MGNT exhibit a common and
stable surface antigen and proteomic profile, as well as
some features of stem/progenitor cells in long-term
cultures.
MGNT-derived spheres contain tumor-initiating cells
Karyotype analysis and in vivo behavior upon orthotopic
grafting were performed in order to determine whether
the cell-forming spheres derived from MGNTs were
indeed tumoral and behaved as tumor-initiating cells
(TICs).
Karyotype analysis was performed on cells collected
from spheres grown from 4 tumors (TG1, TG6, TG7,
TG10). Gains were observed for each cell examined on
chromosomes 1q, 5, 7, 9q, 12, and 14, whereas losses
were observed on chromosomes 9p and 18q (Fig 4).
To determine the presence of TICs, MGNT-derived
sphere cells from four different MGNTs were grafted
into the brain of nude mice (2 mice each, 200-1000 liv-
ing cells per graft). The recipients were sacrificed from
12 to 24 weeks post-graft. Tissue analysis after hematox-
ylin/eosin and immunolabeling with antibodies that
recognized only the human form of the glial marker
vimentin identified human cells in 7 out of 8 mice. In
six cases out of seven, the grafts had developed with cell
proliferation (as evidenced by Mcm2 labeling), and
migration over large distances from the injection site
(Fig 5). Several migrating cells were observed along the
neural fiber axis (Fig 5).
Figure 2 Expression of surface antigens by from freshly
dissociated MGNTs cells and MGNT-derived cells forming
spheres in culture. A. Control IgGs. B. Fresh tumors were
dissociated enzymatically with trypsin and immediately
immunolabeled with either CD133 (left panel) or CD34 (right panel).
C. MGNT-derived cellular spheres were dissociated mechanically as
described (see text), and immunolabeled. Cells were analyzed by
flow cytometry and the positive gates indicated were defined based
on analysis done after double labeling with FITC- or PE-labeled
isotype-matched non-immune immunoglobulin and another
specific antibody. Results are expressed in a morphological gate
including all viable nucleated cells. Data shown are from one
experiment out of three giving similar results.
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Taken altogether these data demonstrate that long-
term cultured MGNT-derived floating spheres contain
tumor cells with neural stem/progenitor phenotype, thus
fulfilling the criteria of tumor initiating cells (TICs).
TICs resist to high concentrations of temozolomide
Temozolomide, an oral alkylating agent, is the main
drug used for high grade gliomas. The therapeutic con-
centration given to patients is around 60 μM. Cells cul-
tured from tumors TG1 at three different passages,
TG10 and TG16 were exposed for 48h to different con-
centrations of temozolomide. Cells from all cultures
were highly resistant to temozolomide, 60% of the cells
being still viable in presence of 1000 μM temozolomide
(Table 6). No difference in temozolomide resistance was
noted between long-term cultured spheres obtained
from FACS-sorted CD133+ and CD133- cells. In addi-
tion, removal of growth factors for 10 days or induction
of differentiation for 7 days in the presence of 10% FCS
did not change TIC resistance to TMZ.
Discussion
Tumor stem cells or tumor-initiating cells with stem-
like properties (TICs) name a small subpopulation of
tumor cells that are clonogenic and are capable of form-
ing a tumor mass mimicking the original one. The pre-
sent work reports on the characterization of tumor
initiating cells from 12 cases of a newly characterized
form of human adult glioma. These cells exhibit long-
term stability in culture, and properties that support
their capacity to establish a novel brain tumor from a
few cells at least up to two years of continuous passages.
Within the array of brain tumors studied in this work,
only MGNTs [20] yielded at a high frequency cells
forming spheres in culture (12 of 15 tumors). In con-
trast, cells proliferating as spheres from glioblastomas,
adult medulloblastoma and ganglioglioma were rapidly
lost upon serial passages after 4 to 6 months in accor-
dance with previous studies [3,4]. Most studies of glio-
blastomas have identified tumor stem cells in only half
or less of the glioblastomas studied [3,4]. Our results
raise the possibility that some of the glioblastomas
assayed in these studies belong to the MGNT sub-class.
Review of 200 glioblastomas showing that 50% of them
contain cells expressing NFP and GFAP supports such a
possibility (PV and CDD, unpublished observations).
The presence of a few tumor cells co-expressing neuro-
nal and glial antigens is one MGNT characteristic,
which can be easily looked for [20]. In addition, our
large set of cultured oligodendrogliomas (WHO grade II
or III) never yielded any sphere and/or cells expressing
a stem-like phenotype. In good agreement with this, no
long-term culture from human oligodendroglioma has
yet been reported. Determination of the presence or
absence of tumor stem cells is, however, insufficient in
the present state of knowledge to conclude that
MGNTs, medulloblastomas and some glioblastomas
result from the targeting of transforming mutations to
an early progenitor/stem-like cell, whereas oligodendro-
gliomas result from mutations accumulating in a more
differentiated cell.
CD133 expression, because expressed also by normal
neural stem cells, has been proposed to identify cells at
the top of the hierarchy formed by tumor stem cells and
their more differentiated progeny, and to be therefore
the paramount of glioma stem cells. Its pertinence as a
glioma stem cell marker is now highly controversial,
several groups having demonstrated the tumor initiating
properties of CD133- cells [27]. In our hands, CD133
was rapidly down-regulated in cell spheres grown in
vitro, whereas expression of other stem cell markers
such as CD15 or CD34 was maintained. CD133- cells
were also able to form floating cellular spheres with
properties undistinguishable from those of CD133+
cells. Similarly, long-term cultured sphere forming cells,
whatever established from CD133+ or CD133- tumor
cells were equally resistant to temozolomide. CD133
expression most likely reflects the bioenergetics stress of
Table 3 Phenotypic characterization of cell-forming
spheres.
% of wells containing spheres Number of sphere/well
CD15- 11/11 = 100% 15 ± 2.2 (day 21)
CD15+ 9/13 = 70% 5.9 ± 2.6 (day 21)
CD34- 14/14 = 100% 22 ± 4.1 (day 36)
CD34+ 12/15 = 80% 20 ± 3.6 (day 36)
Non SP 10/10 = 100% 18.6 ± 0.5 (day 36)
SP 10/10 = 100% 19.1 ± 0.2 (day 36)
Cells cultured as spheres from either TG1, TG6 or TG7 were dissociated and
sorted according to their expression of CD15, CD34 or they capability to
exclude Hoechst 3342 dye. Sorted cells were then plated (100 cells/well) in
round-bottomed 96-well plates and fed once a week. Wells were examined at
days 21 and 36, and the number of spheres (with more than 50 cells) per well
was recorded. Data are from 1 representative experiment out of 3.
Table 4 Expression of stemness markers by MGNT-
derived cells forming spheres.
Samples OCT4/POU5F1 NANOG HTERT CD133/PROM1
TG1 5937 a 1240 131 5
TG6 11857 1959 165 12
TG10 1686 169 517 3
TG16 871 611 73 14
OCT4/POU5F1, NANOG, HTERT and CD133/PROM1 genes expressions were
evaluated using real-time quantitative PCR in 4 MGNT-derived cells forming
spheres. Tests were done with cultures at passage 30 ± 5. Data are from one
experiment out of three giving similar results. a N-fold differences in target
gene expression relative to the smallest amount of target gene mRNA
detectable and quantifiable by real-time quantitative RT-PCR assays (target
gene Ct value = 35; Ntarget value = 1).
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the cells rather than their stem-like properties [28].
CD15, also known as SSEA1 or Lewis X, has also been
recently proposed as an enrichment marker of glioma
TICs [29]. Although we observed some differences in
sphere sizes and proliferation rates between CD15 posi-
tive and negative cells during the first week after sorting,
these variations disappeared with obtaining the second-
ary spheres, which in both cases contained a mixture of
CD15+ and CD15- cells.
Conclusions
We previously reported that MGNTs represent a clini-
cal entity with distinct clinical, anatomo-pathological
and radiological behaviors. We now show that they
have also a distinct biological behavior among high-
grade glial tumors. The glioma initiating cells described
here establish a novel model that may be used to routi-
nely establish adult human tumoral cell lines stable in
long-term cultures in a define medium in a
Figure 3 Proteomic patterns of MGNT-derived cells forming spheres. Upper panel: two-dimensional gel electrophoresis analysis for TG1,
one of the cultures of MGNT-derived cells forming spheres, TG1, at 40 (left) and 160 (right) weeks of culture. Lower panel: the same area of the
gel as in the upper panels for protein extracts taken from two other cultures of MGNT-derived cells forming spheres, TG6 and TG7.
Table 5 MALDI MS/MS characterization of proteins overexpressed in MGNT-derived cells forming spheres.
Entry SwissProt Masse Pi % cover Identification
RET1_HUMAN 15879.92 4,99 60 (P09455) Retinol-binding protein I
SORCN_HUMAN 21947.46 5,32 30 (P30626) Sorcin (22 kDa protein) (CP-22) (V19)
GSTP1_HUMAN 23438.07 5,44 27 (P09211) Glutathione S-transferase P (EC 2.5.1.18)
PRDX6_HUMAN 25002.19 6,02 25 (P30041) Peroxiredoxin 6 (EC 1.11.1.15)
ECHM_HUMAN 31823.30 8,34 29 (P30084) Enoyl-CoA hydratase
HSPB1_HUMAN 22825.51 5,98 66 (P04792) Heat-shock protein beta-1 (HspB1)
M6PBP_HUMAN 47189.00 5,30 53 (O60664) Mannose-6-phosphate receptor binding protein 1
Q96E67_HUMAN 40542.00 5,55 32 (Q96E67) ACTB protein (Fragment)
The proteins listed in the table were only detected in 2D-SDS silver stained gels obtained from MGNT-derived cells forming spheres and not observed in the
corresponding gel obtained with the same amount of proteins extracted from the original brain tumor. The proteins were identified by mass spectrometry
analysis.
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Figure 4 Karyotype. Chromosomal analysis of TG1 cells by Multi FISH reveals a hypotriploidy with an over-representation of chromosomes 7
and 14, and one chromosome 11q+.
Figure 5 Intra-cerebral grafts. MGNT-derived cells forming spheres were grafted in the dorsal striatum of immunodeficient mice (inset in panel
B). Mice were sacrificed from 12 to 22 weeks post-graft and brain sections immunostained. A. Hematoxylin-eosin staining was performed to
identify tumor mass (inset: a cell undergoing mitosis within the tumor mass). B. Identification of human cells with an antibody specific of the
human vimentin (brown). C-D. Double immunolabeling for vimentin (brown) and minichromosome maintenance 2 (mcm2, red nuclear labeling)
identified cycling human cells (arrows). Cells were able to migrate at distance from the site of injection (D). Scale bar: 100 μm in B, 50 μm in A,
20 μm in C, D and inset in A. B-D: floxin counterstaining.
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reproducible fashion. This may open new ways to iden-
tify novel tumor cell markers and surface receptor pro-
files for therapeutic and diagnostic purposes and to
develop patient-tailored pharmacologic approaches for
the cure of gliomas.
List of abbreviations used
TIC: tumor initiating cells; MGNT: Malignant glio-neu-
ronal tumors
Additional file 1: Maintenance of tumoral architecture and cell
viability in organotypic cultures of human brain tumors.
Immunohistochemical staining of an original MGNT tumor (upper panels)
and after 4 weeks in organotypic culture (lower panels). The tumor
samples were collected by an anatomopathologist in the surgical room,
sliced into small fragments (less than 1 mm3), and layered on surgical
sponge fragments floating over a culture medium composed of RPMI
with 6% FCS. These organotypic cultures were maintained up to 6 weeks
without visible alteration of the tumoral architecture, as compared to the
original histological examination.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2407-10-
66-S1.PDF ]
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